Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista) header
Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista) profile picture

MD,MSc (@Harvard)๐ŸŽ—Medical Oncologist | Breast CA Specialist & Researcher ๐Ÿงฌ | ๐Ÿ‡บ๐Ÿ‡ธ๐Ÿ‡ช๐Ÿ‡บ Board Certified โ€” Assoc Lecturer in Med Oncol Member of @ASCO | @MyESMO

Manhattan, NY
Joined August 2019
Photo by Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista)Photo by Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista)Photo by Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista)Photo by Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista)Photo by Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista)Photo by Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista)Photo by Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista)Photo by Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista)Photo by Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista)Photo by Aya Mohamed | MSc, MD ๐ŸŽ— (@Dr_Oncologista)
After years of hard work and dedication, I'm blessed to say that I have successfully passed Board exam for the European Society for Medical Oncology #ESMO examination 2024 as well.
31
7
1
135
29,888
Aya Mohamed | MSc, MD ๐ŸŽ— retweeted
OUT TODAY!! THE COMPLETE #ESMO26 NEWSLETTER ๐Ÿ“ฐ Bringing together our top picks from the most important trials presented in Madrid, all in one email. ๐Ÿ“ฉ Register to receive it: buff.ly/N5gYtAc Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest. We are OncoAlert ๐Ÿšจ โ€” For Colleagues, by Colleagues. Best, The OncoAlert Network @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
๐Ÿค– Made with AI
12
3
18
2,316
Aya Mohamed | MSc, MD ๐ŸŽ— retweeted
Thank you Colleagues for a phenomenal #ESMO26 ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. ๐ŸŒ OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME. ๐Ÿ“ฃ 101.7M impressions of potential reach ๐Ÿ’ฌ 6.1K posts on X from 988 participants in 34 countries โšก 43.1 posts per hour across the meeting days ๐Ÿ˜Š 45% positive sentiment, with only 6% negative Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO ๐Ÿ† Top influencers @DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista ๐ŸŒŽ Where the conversation came from North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities. ๐Ÿ”ฌ Top studies by impact 1๏ธโƒฃ DeLLphi-305 (SCLC): 4.0M reach, 170 posts 2๏ธโƒฃ VOLGA (bladder): 3.7M reach, 141 posts 3๏ธโƒฃ KRASCENDO-1 (NSCLC): 3.5M reach 4๏ธโƒฃ SAFFRON (NSCLC): 3.3M reach 5๏ธโƒฃ INTerpath-001 (melanoma): 154 posts Pinging our Collaborators
17
4
45
9,312
Aya Mohamed | MSc, MD ๐ŸŽ— retweeted
TroFuse-005, investigational: โ€œThat is clinically meaningful and warrants use.โ€ โ€œThe tox is a concern.โ€ โ€” @DrKatyMoore KEYNOTE-C93 (@Merck): โ€œImportant caveat: Comparator was chemotherapy alone, NOT the current chemo-immunotherapy standard.โ€ โ€” @SuyogCancer hubs.ly/Q04CnqTR0
2
162
Aya Mohamed | MSc, MD ๐ŸŽ— retweeted
BFv Showed Activity in Pretreated Metastatic Triple-Negative Breast Cancer After Prior Top1i-ADC Exposure - Aya Mohamed @Dr_Oncologista oncodaily.com/science/aya-moโ€ฆ
3
3
7
275
Aya Mohamed | MSc, MD ๐ŸŽ— retweeted
Dear colleagues, We are already curating THE COMPLETE #ESMO26 NEWSLETTER ๐Ÿ“ฐ our picks of the top trials presented in Madrid, together in one email. Register to receive it ๐Ÿ‘‰ buff.ly/N5gYtAc Every newsletter is curated by oncologists, for colleagues working in cancer care. Itโ€™s our way of making science quick and accessible. We are OncoAlert๐Ÿšจ For Colleagues, by Colleagues Best, The Network @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
2
26
12
44
9,843
Aya Mohamed | MSc, MD ๐ŸŽ— retweeted
Day 1 of #ESMO26 ๐Ÿ’ป๐Ÿ“š Following the latest in oncology. ๐Ÿงฌ @OncoAlert
4
4
48
1,048
ASTRIDE:๐Ÿซ Serplulimab + chemotherapy showed a numerical OS advantage over atezolizumab + chemotherapy in 1L ES-SCLC (12.4 vs 10.2 months; HR 0.82). @OncoAlert #ESMO26 #LungCancer #ESMOAmbassadors #Lcsm #ESMOcommunity @myESMO
4
7
15
899
๐Ÿ“Š Despite higher 2 year OS (32.2% vs 17.6%), the nearly identical PFS (HR 0.95) makes the survival signal difficult to interpret.
5
150
DeLLphi-304: ๐Ÿซ Tarlatamab sustained its OS benefit at 23-month follow-up, improving median OS to 13.6 vs 8.4 months (HR 0.62) @OncoAlert #ESMO26 @ESMO_Open #ESMOAmbassadors #LungCancer #ESMOcommunity @myESMO
๐Ÿ“ข #ESMO26 concomitant paper: Extended follow-up of #tarlatamab in patients with small-cell lung cancer after platinum-based chemo in the phase 3 DeLLphi-304 study. ๐Ÿ”—shorturl.at/QFAwC @JulienMazieres @pedrofrocha @UniklinikEssen @medizinischefakultaet @g_mountzios
1
9
21
774
Durable disease control in a subset of patients, with less grade 3 or higher toxicity than chemotherapy. CRS and ICANS remain key considerations.
6
122
OptiTROP-Breast01: Sac-TMT improved median OS in pretreated mTNBC (14.7 vs 9.9 months; HR 0.60), reinforcing the role of ADCs in later-line treatment. @OncoAlert #ESMO26 #ESMOAmbassadors #ESMOcommunity @myESMO #BreastCancer #bcsm
1
10
22
715
DESTINY-Breast09: #ESMO26 T-DXd + pertuzumab showed encouraging systemic and intracranial activity in 1L HER2+ mBC with baseline brain metastases, with CNS-PFS HR 0.26 vs THP. @OncoAlert #BreastCancer #bcsm #ESMOAmbassadors #ESMOcommunity @myESMO
2
10
27
886
A compelling signal, but how will these data shape first-line treatment decisions?
1
5
141
INSPIRE-LM: In HER2+ leptomeningeal metastases, radiotherapy followed by intrathecal trastuzumab/pertuzumab showed a median OS of 36.2 months and median LM-PFS of 19.3 months. @OncoAlert #BreastCancer #ESMO26 #ESMOAmbassadors #BCSM #ESMOcommunity @myESMO
1
7
16
560
Striking phase II results, but the single-arm design limits causal conclusions. Prospective validation remains essential.
5
99
HER2-CR: Persistent ctDNA negativity may help identify long-term responders with HER2+ MBC who could be candidates for anti-HER2 treatment discontinuation. Prospective validation is essential before using ctDNA to guide treatment cessation. @OncoAlert #ESMO26 @kazuki_nozawa
1
8
17
705
OptiTROP-Lung06:๐Ÿซ Sac-TMT + pembrolizumab improved median PFS in PD-L1โ€“negative advanced nonsquamous NSCLC (15.0 vs 5.7 months; HR 0.49), with fewer grade 3 or higher adverse events. OS remains immature; follow-up is key. @OncoAlert #ESMO26 #LungCancer #ESMOcommunity @myESMO
Original Article: Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1โ€“Negative Advanced NSCLC (phase 3 OptiTROP-Lung06 trial) nej.md/4Bo3liu #ESMO26 | @myESMO
8
17
688
Beyond Target Loss: T-DXd Resistance Drug efflux and altered internalization may contribute to resistance, challenging how we approach post-ADC sequencing. @OncoAlert #ESMO26 #BreastCancer #bcsm #ESMOAmbassadors #ESMOcommunity @myESMO
9
18
523